<DOC>
	<DOCNO>NCT00005967</DOCNO>
	<brief_summary>Randomized phase I trial study effectiveness tipifarnib treat patient advanced hematologic cancer . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Tipifarnib Treating Patients With Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine relationship tipifarnib dose inhibition farnesylation malignant cell patient advance hematologic malignancy . II . Determine safety profile drug patient population . III . Determine clinical activity drug patient . OUTLINE : This randomize study . Patients randomize 1 4 dose level . Patients receive oral tipifarnib twice daily 21 day . Courses repeat every 28 day absence disease progression unacceptable toxicity . After 1 course therapy , patient may receive subsequent therapy maximum tolerate dose investigator 's discretion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hematologic malignancy refractory standard therapy know effective therapy exist Hodgkin 's nonHodgkin 's lymphoma Known bone marrow involvement Acute myeloid leukemia Chronic myelogenous leukemia Chronic phase No significant symptom treatment No feature accelerate phase blastic phase Accelerated phase WBC difficult control conventional busulfan hydroxyurea term dose requirement shorten interval course Rapid double WBC ( less 5 day ) At least 10 % blast blood marrow At least 20 % blast plus promyelocytes blood marrow At least 20 % basophils plus eosinophils blood Anemia thrombocytopenia unresponsive busulfan hydroxyurea Persistent thrombocytosis Additional chromosome change Increasing splenomegaly Development chloromas myelofibrosis Blastic phase At least 30 % blast plus promyelocytes blood bone marrow Acute lymphoblastic leukemia Chronic lymphocytic leukemia Myelodysplastic syndromes Refractory anemia excess blast ( RAEB ) Chronic myelomonocytic leukemia RAEB transformation Multiple myeloma Chronic myeloproliferative disease include , limited , myelofibrosis myeloid metaplasia Measurable evaluable disease document radiographic , hematologic , bone marrow , clinical examination parameter Refusal allogeneic bone marrow transplantation allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Hepatic : Bilirubin great 1.5 mg/dL Albumin least 2.5 g/dL Renal : Creatinine le 2.0 mg/dL Other : No uncontrolled medical disorder No active inflammatory bowel disease , ileus , chronic malabsorption syndromes Not pregnant nursing Fertile patient must use effective contraception 2 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) At least 3 day since prior hydroxyurea Endocrine therapy : At least 4 week since prior systemic steroid multiple myeloma Radiotherapy : At least 4 week since prior radiotherapy Surgery : No prior total gastrectomy total ileocolectomy Other : No prior tipifarnib No concurrent proton pump inhibitor ( e.g. , omeprazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>